Menu
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow1.44 B USD989.50 M USD748.50 M USD669.50 M USD442.50 M USD475.60 M USD314.50 M USD123.20 M USD92.00 M USD56.20 M USD49.00 M USD23.60 M USD
Depreciation & Amortization251.80 M USD217.70 M USD186.00 M USD155.90 M USD102.00 M USD67.10 M USD48.70 M USD29.10 M USD16.10 M USD15.00 M USD10.80 M USD8.40 M USD
Stock-Based Compensation159.60 M USD170.40 M USD150.80 M USD126.50 M USD113.40 M USD119.40 M USD102.70 M USD101.90 M USD106.20 M USD110.80 M USD82.70 M USD50.00 M USD
Capital Expenditures363.50 M USD358.80 M USD236.60 M USD364.80 M USD389.20 M USD199.00 M USD180.00 M USD67.10 M USD66.00 M USD55.70 M USD33.30 M USD16.20 M USD
Cash Flow from Investing536.00 M USD-207.50 M USD-507.20 M USD-521.50 M USD-216.10 M USD-1.02 B USD-1.02 B USD-139.80 M USD-144.40 M USD-55.90 M USD-51.50 M USD-16.80 M USD
Cash Flow from Financing-1.69 B USD-734.80 M USD-318.60 M USD-552.50 M USD10.40 M USD912.10 M USD10.70 M USD710.40 M USD399.10 M USD8.10 M USD16.80 M USD21.80 M USD
Dividends Paid
Stock Buybacks500.00 M USD750.00 M USD688.70 M USD557.70 M USD0 USD0 USD0 USD100.00 M USD0 USD0 USD
Free Cash Flow1.08 B USD630.70 M USD511.90 M USD304.70 M USD53.30 M USD276.60 M USD134.50 M USD56.10 M USD26.00 M USD500000 USD15.70 M USD7.40 M USD

DexCom, Inc. is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems for diabetes management. Its primary products deliver real-time glucose readings through small, wearable sensors that provide accurate, personalized data to users, simplifying daily monitoring and decision-making for people with diabetes. The company's CGM platforms integrate seamlessly with smartphones and insulin delivery devices, enabling features like customizable alerts, trend analysis, and sharing capabilities for caregivers and healthcare providers. DexCom, Inc. focuses on advancing glucose biosensing technology to enhance patient outcomes across all age groups, from children to adults. Its solutions support healthcare professionals in clinical settings and empower individuals with actionable insights for better glycemic control. Founded in 1999 and headquartered in San Diego, California, DexCom, Inc. plays a vital role in the diabetes care sector, driving innovation in remote monitoring and connected health ecosystems within the broader medical device industry.